Merck

Temprian Therapeutics Finalist in Nature Merck Spinoff 2020 Competition

Thursday, July 2, 2020 - 5:00pm

CHICAGO, July 2, 2020 /PRNewswire-PRWeb/ --Temprian, a spinoff from Northwestern University, has a platform technology intended for the treatment of autoimmune diseases.

Key Points: 
  • CHICAGO, July 2, 2020 /PRNewswire-PRWeb/ --Temprian, a spinoff from Northwestern University, has a platform technology intended for the treatment of autoimmune diseases.
  • Temprian's selection as a finalist for the Nature Spinoff Prize provides hope for securing finances needed for a clinical trial.
  • The Spinoff Prize has been established by the journal Nature in partnership with Merck KGaA to showcase and celebrate global excellence in the commercialization of research through the creation of spinoff companies.
  • ABOUT Nature, Merck KGaA and the Spinoff Prize 2020: The Spinoff Prize has been established by the journal Nature Research in partnership with Merck to showcase and celebrate global excellence in the commercialization of research through the creation of spinoff companies.

Menarini Ricerche Announces C-PRECISE-01, a New Phase Ib/II Trial of MEN1611 in Colorectal Cancer

Thursday, July 2, 2020 - 12:00pm

The new study, called C-PRECISE-01, will evaluate MEN1611 and cetuximab in patients with PIK3CA mutated, RAS and RAF wild-type metastatic colorectal cancer (mCRC), failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens.

Key Points: 
  • The new study, called C-PRECISE-01, will evaluate MEN1611 and cetuximab in patients with PIK3CA mutated, RAS and RAF wild-type metastatic colorectal cancer (mCRC), failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens.
  • MEN1611 is an oral PI3K inhibitor active on the p110, and isoforms, while sparing the .
  • Preclinical and clinical evidence supports the development of MEN1611 in combination with other agents in the context of solid tumors.
  • Through the work of Menarini Silicon Biosystems, Menarini is also developing advanced technologies and products to study rare cells with single-cell precision.

Menarini Ricerche Announces C-PRECISE-01, a New Phase Ib/II Trial of MEN1611 in Colorectal Cancer

Thursday, July 2, 2020 - 8:00am

The new study, called C-PRECISE-01, will evaluate MEN1611 and cetuximab in patients with PIK3CA mutated, RAS and RAF wild-type metastatic colorectal cancer (mCRC), failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens.

Key Points: 
  • The new study, called C-PRECISE-01, will evaluate MEN1611 and cetuximab in patients with PIK3CA mutated, RAS and RAF wild-type metastatic colorectal cancer (mCRC), failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens.
  • MEN1611 is an oral PI3K inhibitor active on the p110, and isoforms, while sparing the .
  • Preclinical and clinical evidence supports the development of MEN1611 in combination with other agents in the context of solid tumors.
  • Through the work of Menarini Silicon Biosystems, Menarini is also developing advanced technologies and products to study rare cells with single-cell precision.

Merck Animal Health Completes Acquisition of U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals

Thursday, July 2, 2020 - 7:00am

Our veterinary medicines, including parasiticides, and vaccines continue to transform the animal health industry and further solidify our position in the U.S. Companion Animal category, said Rick DeLuca, president, Merck Animal Health.

Key Points: 
  • Our veterinary medicines, including parasiticides, and vaccines continue to transform the animal health industry and further solidify our position in the U.S. Companion Animal category, said Rick DeLuca, president, Merck Animal Health.
  • Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of Merck.
  • Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them.
  • Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets.

Merck and Ridgeback Bio Announce Closing of Collaboration and Licensing Transaction

Wednesday, July 1, 2020 - 9:30pm

Under the agreement, announced on May 26, 2020, Merck, through a subsidiary, has acquired exclusive worldwide rights to develop EIDD-2801 and related molecules in collaboration with Ridgeback.

Key Points: 
  • Under the agreement, announced on May 26, 2020, Merck, through a subsidiary, has acquired exclusive worldwide rights to develop EIDD-2801 and related molecules in collaboration with Ridgeback.
  • Ridgeback will continue to fund and conduct multiple Ridgeback-sponsored Phase 1 and 2 trials and fund manufacturing campaigns for clinical supply.
  • Going forward, the parties will collaborate on clinical development for COVID-19 and manufacturing, to be led by Merck.
  • Merck and Ridgeback are committed to ensure that any medicines developed for SARS-CoV-2 will be accessible and affordable globally.

FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Tuesday, June 30, 2020 - 11:45pm

For patients that do not progress on platinum-containing chemotherapy, BAVENCIO is administered as a first-line maintenance treatment until disease progression or unacceptable toxicity.

Key Points: 
  • For patients that do not progress on platinum-containing chemotherapy, BAVENCIO is administered as a first-line maintenance treatment until disease progression or unacceptable toxicity.
  • BAVENCIO (avelumab) is indicated in the US for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.
  • In the US, the FDA granted accelerated approval for BAVENCIO for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).
  • A fatal adverse reaction (sepsis) occurred in one (0.3%) patient with locally advanced or metastatic urothelial carcinoma (UC) receiving BAVENCIOplus best supportive care (BSC) as first-line maintenance treatment.

Celltrion Healthcare Receives Positive CHMP Opinion for an Additional Five Indications for Remsima® SC Including for Use in Inflammatory Bowel Disease and Ankylosing Spondylitis

Monday, June 29, 2020 - 12:03am

The subcutaneous formulation can be administered by patients themselves, thereby providing alternative treatment options giving them greater flexibility and control.

Key Points: 
  • The subcutaneous formulation can be administered by patients themselves, thereby providing alternative treatment options giving them greater flexibility and control.
  • Since its first launch, Remsima has been used for more than 5 years in over 90 countries.
  • This positive CHMP opinion is very encouraging and brings us closer to improving outcomes for more patients who are eligible to receive the subcutaneous formulation, said Hyoung-Ki Kim, Vice Chairman at Celltrion Healthcare.
  • Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 120 different countries.

Highlight Therapeutics announces first patient dosed in Phase IIa study in liver metastasis

Friday, June 26, 2020 - 8:00am

MADRID, Spain, June 26, 2020 (GLOBE NEWSWIRE) -- Highlight Therapeutics ("Highlight"), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, announces the dosing of the first patient in a Phase IIa clinical evaluation of the combination of BO-112, Highlight's lead program, and KEYTRUDA (pembrolizumab), MSD's anti-PD-1 therapy, in patients with select advanced stage solid tumors with liver metastases.

Key Points: 
  • MADRID, Spain, June 26, 2020 (GLOBE NEWSWIRE) -- Highlight Therapeutics ("Highlight"), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, announces the dosing of the first patient in a Phase IIa clinical evaluation of the combination of BO-112, Highlight's lead program, and KEYTRUDA (pembrolizumab), MSD's anti-PD-1 therapy, in patients with select advanced stage solid tumors with liver metastases.
  • Click on, or paste the following link into your web browser, to view the associated PDF document.
  • This information is provided by RNS, the news service of the London Stock Exchange.
  • RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

NeoImmuneTech Announces First Patient Dosed in Phase 1b/2a Study of NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in Patients with Relapsed/Refractory Advanced Solid Tumors

Thursday, June 25, 2020 - 12:00pm

Dosing the first patient in this study marks a major milestone in the development of NT-I7 for the treatment of patients with advanced solid tumors, said NgocDiep Le, M.D., Ph.D., Executive VP and Chief Medical Officer of NeoImmuneTech.

Key Points: 
  • Dosing the first patient in this study marks a major milestone in the development of NT-I7 for the treatment of patients with advanced solid tumors, said NgocDiep Le, M.D., Ph.D., Executive VP and Chief Medical Officer of NeoImmuneTech.
  • We will investigate clinically NT-I7s potential to augment the already proven anti-tumor activity of pembrolizumab in CPI-responsive tumors.
  • We hope that NT-I7 in combination with KEYTRUDA can improve the lives of cancer patients with various solid tumors.
  • The goal of the Phase 1b portion of the study, which will enroll up to 18 patients, is to establish a recommended dosing regimen.

New MyMSTeam Resource Center Educates People Living With Multiple Sclerosis On The Importance of Treatment and Adherence

Wednesday, June 24, 2020 - 5:30pm

"Even under normal circumstances it can be hard for people with MS to stay on their medication," explains Eric Peacock, cofounder and CEO of MyHealthTeams.

Key Points: 
  • "Even under normal circumstances it can be hard for people with MS to stay on their medication," explains Eric Peacock, cofounder and CEO of MyHealthTeams.
  • MyHealthTeams creates social networks for people living with a chronic health condition.
  • EMD Serono - the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada - is engaged in the discovery, research and development of medicines for patients with difficult to treat diseases.
  • The business is committed to transforming lives by developing and delivering meaningful solutions that help address the therapeutic and support needs of individual patients.